Quantbot Technologies LP Purchases New Stake in Twist Bioscience Corporation $TWST

Quantbot Technologies LP bought a new position in Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 18,849 shares of the company’s stock, valued at approximately $1,939,000.

A number of other institutional investors have also modified their holdings of TWST. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 24.4% in the second quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares during the period. Stifel Financial Corp lifted its stake in Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock valued at $246,000 after purchasing an additional 271 shares during the last quarter. D.A. Davidson & CO. lifted its position in shares of Twist Bioscience by 1.2% during the 4th quarter. D.A. Davidson & CO. now owns 25,237 shares of the company’s stock valued at $801,000 after acquiring an additional 305 shares during the last quarter. CWM LLC increased its stake in Twist Bioscience by 9.4% in the 4th quarter. CWM LLC now owns 4,738 shares of the company’s stock worth $150,000 after purchasing an additional 407 shares in the last quarter. Finally, California State Teachers Retirement System lifted its stake in Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock valued at $1,994,000 after buying an additional 442 shares in the last quarter.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the sale, the chief financial officer directly owned 110,276 shares in the company, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Dennis Cho sold 14,205 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the transaction, the insider directly owned 105,141 shares of the company’s stock, valued at $9,436,404.75. This represents a 11.90% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 151,529 shares of company stock worth $17,708,772 over the last quarter. 3.08% of the stock is currently owned by corporate insiders.

Twist Bioscience Stock Performance

Shares of NASDAQ:TWST opened at $140.80 on Tuesday. The firm’s 50 day simple moving average is $101.89 and its 200 day simple moving average is $71.16. The company has a market capitalization of $8.83 billion, a price-to-earnings ratio of -63.42 and a beta of 2.14. Twist Bioscience Corporation has a fifty-two week low of $23.30 and a fifty-two week high of $145.93. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The company had revenue of $118.38 million during the quarter, compared to analyst estimates of $114.55 million. During the same quarter last year, the company earned $0.33 EPS. The firm’s quarterly revenue was up 23.2% compared to the same quarter last year. As a group, sell-side analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

TWST has been the subject of a number of research reports. Canaccord Genuity Group raised their price objective on Twist Bioscience from $90.00 to $120.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. UBS Group set a $89.00 target price on shares of Twist Bioscience in a research report on Monday, June 15th. Evercore downgraded Twist Bioscience from an “outperform” rating to an “in-line” rating and set a $102.00 price target on the stock. in a report on Monday, July 6th. TD Cowen reiterated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 3rd. Finally, Piper Sandler upped their target price on Twist Bioscience from $85.00 to $115.00 and gave the company an “overweight” rating in a research note on Wednesday, August 5th. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $98.30.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.